GLP-1 receptor agonists exhibit considerable effectiveness in facilitating weight reduction and enhancing metabolic parameters pertinent to the pathophysiology of PCOS, including insulin resistance. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.